Prospective, Randomized Study of role of Saroglitazar, vitamin E and lifestyle modification in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)

Anurag Kumar Tiwari0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•Patients with non alcoholic fatty liver disease/ non alcoholic steatohepatitis who will demonstrate understanding of study requirements and treatment procedures, and willing to comply with all protocol-required evaluations.
•Patients having alanine aminotransferase (ALT) elevation of at least 1.5 times of upper limit of normal and liver stiffness measurement of more than 7 Kilo- pascals (KPa).

•1.Present or past (within 2 year of inclusion) alcohol user >20g/day in males; >10g/day in females.
•2.History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, cholestatic and metabolic liver diseases) and hemochromatosis.
•3.Patients with decompensated cirrhosis.
•4.Patients with Thyroid disorders.
•5.Pregnant and lactating females and females who are not willing to use contraception during study period.
•6.Patients with diabetes mellitus, coronary artery disease, uncontrolled hypertension, chronic kidney disease or any chronic systemic illness that in view of investigator would make patient unsuitable for study.
•7.Patients using alternative medicines or ursodeoxycholic acid, Sadenosylmethionine (SAM-e), betaine, pentoxifylline etc for NAFLD during last 1 month from inclusion.

发起方

Anurag Kumar Tiwari